Plasbumin-20 Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Plasbumin-20 market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to several factors, including an increase in the prevalence of chronic diseases, growth in surgical procedures, a rise in demand for critical care solutions, improved diagnostic capabilities, and higher awareness of hypoproteinemia.

Growth during the market's forecast period can be attributed to several factors, including the growing incidence of liver diseases, the rising number of trauma cases, increasing demand for supportive therapies, greater access to healthcare services, and the prevalence of burn and shock cases. Major trends expected to shape the forecast period include enhanced use of albumin in multi-modal therapy, integration of albumin with innovative delivery systems, increased investment in rare disease research, adoption of advanced packaging solutions, and growth in homecare settings for administration.

The rising prevalence of chronic diseases is expected to drive the growth of the plasbumin-20 market in the coming years. Chronic diseases, such as heart disease, diabetes, and arthritis, are long-term conditions that persist for a year or more, often requiring ongoing medical attention and potentially limiting daily activities. The increasing incidence of these diseases can be attributed to factors like an aging population, lifestyle changes, urbanization, and genetic predispositions. As the global prevalence of chronic diseases continues to rise, particularly with aging populations and lifestyle-related factors, the demand for therapies like Plasbumin-20 is set to grow, positioning it as a critical tool in managing long-term healthcare challenges. For example, Macmillan Cancer Support reported in June 2022 that the number of people living with cancer in the UK reached 3 million in 2022, with projections suggesting this number will rise to nearly 3.5 million by 2025 and 4 million by 2030. As such, the increasing prevalence of chronic diseases is a key driver of the plasbumin-20 market.

The global expansion of healthcare infrastructure is anticipated to propel the growth of the plasbumin-20 market. Healthcare infrastructure includes the physical and organizational structures, facilities, resources, and systems necessary to deliver healthcare services. This expansion is being driven by several factors, including the aging population, the rising prevalence of chronic diseases, and advancements in medical technology. Plasbumin-20, a human albumin solution used for plasma protein therapy, is commonly administered to improve clinical outcomes in various medical conditions. For example, in September 2024, statistics from Cross River Therapy revealed that the U.S. pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medicine in 2021. Projections indicate that spending will increase to $605-$635 billion by 2025. This expansion of healthcare infrastructure is, therefore, supporting the growth of the plasbumin-20 market.

The growing aging population is expected to drive further demand for plasbumin-20 in the future. The aging population, defined as individuals aged 65 and older, is growing due to increased life expectancy and declining birth rates. This demographic shift is supported by advancements in healthcare, medical technology, and improved living conditions. Plasbumin-20 plays a crucial role in managing age-related conditions, particularly those related to low protein levels, by enhancing health outcomes and helping older individuals recover from surgeries or trauma. It also strengthens the immune system, contributing to better resilience against age-related medical challenges. For example, the Population Reference Bureau reported in January 2024 that the number of Americans aged 65 and older is expected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. The proportion of older adults in the overall population will also grow from 17% to 23%. As a result, the rising aging population is a significant driver for the plasbumin-20 market.

Key player operating in the plasbumin-20 market is Grifols SA.

North America was the largest region in the plasbumin-20 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the plasbumin-20 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Plasbumin-20 is a human albumin solution derived from pooled human plasma, used primarily to restore and maintain blood volume and protein levels in patients experiencing conditions such as hypovolemic shock, hypoproteinemia, and certain liver disorders. It is commonly used in clinical settings to support patients undergoing surgeries, managing acute liver failure, or treating other medical conditions that result in low blood protein levels.

The main product types in the plasbumin-20 market include human albumin and recombinant albumin, both of which are used to manage a variety of medical conditions. Human albumin is a protein derived from pooled human plasma that helps maintain blood volume and pressure and is used to treat conditions involving low protein levels and fluid imbalance. The primary indications for Plasbumin-20 include hypovolemic shock, hypoproteinemia, ARDS, cardiopulmonary bypass, and acute liver failure. It is distributed through channels such as direct sales, pharmaceutical distributors, and online sales. The users of Plasbumin-20 include both adult and geriatric patients.

The plasbumin-20 market research report is one of a series of new reports that provides plasbumin-20 market statistics, including plasbumin-20 industry global market size, regional shares, competitors with a plasbumin-20 market share, detailed plasbumin-20 market segments, market trends and opportunities, and any further data you may need to thrive in the plasbumin-20 industry. This plasbumin-20 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Plasbumin-20 market consists of sales of Plasbumin 20% injection (100 mL) and Plasbumin 20% infusion (50 mL). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.